文章核心观点 - 沃尔格林(Walgreens)宣布与VillageMD合作,并投资10亿美元扩大合作关系,但实际上Walgreens未能有效部署资本以推动其美国医疗保健业务的增长,也无法实现VillageMD的盈利扩张[3][4] - Walgreens在美国医疗保健业务的增长低于预期,因为Walgreens建立了太多VillageMD诊所,导致这些新建的医疗诊所人手不足,看诊人数较少[4] - Walgreens高管未能管理好投资者对VillageMD价值的预期,也未能充分披露VillageMD扩张对公司短期利润的负面影响[4] 根据目录分类总结 公司业务情况 - Walgreens是美国和国际市场上最大的零售、药房和医疗保健服务提供商,业务分为三个板块:美国零售药房、国际业务和美国医疗保健[3] - 2019年,Walgreens宣布与VillageMD合作,VillageMD将在Walgreens门店旁开设初级医疗诊所,这一合作关系被认为取得了成功,导致Walgreens对VillageMD追加10亿美元投资并扩大合作[3] 公司经营问题 - Walgreens未能有效部署资本以推动其美国医疗保健业务的增长,也无法实现VillageMD的盈利扩张[4] - Walgreens在美国医疗保健业务的增长低于预期,因为Walgreens建立了太多VillageMD诊所,导致这些新建的医疗诊所人手不足,看诊人数较少[4] - Walgreens高管未能管理好投资者对VillageMD价值的预期,也未能充分披露VillageMD扩张对公司短期利润的负面影响[4] 公司财务表现 - 2023年6月27日,Walgreens公布了2023财年第三季度的业绩,业绩不佳,并下调了2023年全年指引,称"美国医疗保健业务的利润增长较慢",这是由于VillageMD的业绩不佳所致,公司股价下跌9.3%[5] - 2024年1月4日,Walgreens公布了2024财年第一季度的业绩,业绩不佳,分析师将其归咎于VillageMD诊所的运营,公司股价下跌5%[6] - 2024年6月27日,Walgreens公布了2024财年第三季度的业绩,业绩不佳,同时宣布将减少对VillageMD的持股,不再成为其多数股东,公司股价下跌22%[6] 管理层变动 - 2023年7月27日,Walgreens宣布首席财务官离职,公司股价下跌近3%[5] - 2023年9月1日,Walgreens宣布首席执行官离职,公司股价下跌7.4%[5]

The most recent trading session ended with Walgreens Boots Alliance (WBA) standing at $9.01, reflecting a -0.55% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily loss of 0.29%. At the same time, the Dow lost 0.25%, and the tech-heavy Nasdaq lost 0.31%.Coming into today, shares of the largest U.S. drugstore chain had lost 15.56% in the past month. In that same time, the Retail-Wholesale sector gained 4.15%, while the S&P 500 gained 1.57%.Investors will b ...

BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Saxena White P.A. has filed a securities fraud class action lawsuit (the “Class Action”) in the United States District Court for the Northern District of Illinois against Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) and certain of its executive officers (collectively, “Defendants”). The Class Action asserts claims under Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 (the “Exchange Act”) and U.S. Securiti ...

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Walgreens Boots Alliance, Inc. (NASDAQ: WBA) on behalf of long-term stockholders following a class action complaint that was filed against Walgreens on July 12, 2024 with a Class Period from October 12, 2023 to June 26, 2024. Our investigation concerns whether the board of directors of Walgreens have breached their fiduciary duties to the co ...

It could be smaller, but more financially sustainable if things go as planned.While you've probably had a consistent experience going to the pharmacies operated by Walgreens Boots Alliance (WBA 4.19%) over the years, that doesn't make it a company that's in stasis. In fact, within the next three years, there's a very high chance that it'll be changing in a handful of ways that are relevant to investors.But even if the retail experience doesn't shift much, there's reason to believe that the stock's value wil ...

Its challenges are formidable, so only certain investors should consider it.As the great investor Peter Lynch once suggested, investing in companies that you know well and interact with every day can be a great way to exercise an edge and make a profit. But that doesn't mean you should invest in every company you know well.On that note, Walgreens Boots Alliance (WBA 4.19%) is a business that many of us are customers of, and often for many years. Yet it probably isn't the best choice for investors who prefer ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Walgreens Boots Alliance, Inc. ("Walgreens" or the "Company") (NASDAQ: WBA) investors of a class action representing investors that bought securities between October 12, 2023 to June 26, 2024, inclusive (the "Class Period"). Walgreens investors have until September 10, 2024 to file a lead plaintiff motion. Investors are encouraged to contact a ...

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) TD Cowen 9th Annual FutureHealth Conference September 10, 2024 4:10 PM ET Company Participants Ramita Tandon - Chief Clinical Trial Officer Conference Call Participants Charles Rhyee - TD Cowen Charles Rhyee All right. I think, we're going to get started with our last session of the day, and thanks everyone for sticking around here. So, in June of '22, Walgreens launched its clinical trial business, which utilizes Walgreens national retail pharmacy footprint to pr ...

会议主要讨论的核心内容 - 公司在2022年6月推出了临床试验业务 [1][2] - 该业务利用公司遍布全国的零售药店网络提供患者招募、试验执行和真实世界证据服务 [1][2] - 该业务已发展成为一个盈利的业务部门 [2] - 公司提供三大服务:洞见驱动的患者招募、试验执行和实世界证据信息学 [4][5][6][9] - 公司可以在多个治疗领域提供支持 [11] - 公司利用药剂师在社区中的地位和信任来推动临床试验 [13][14][16][17] - 公司是唯一一家提供成熟临床试验服务的零售药店 [20] - 公司在获取和代表性不足的社区患者方面具有独特优势 [22][23] 问答环节重要的提问和回答 - 问:公司在获取代表性不足的社区患者方面有什么成功案例 [24] 答:公司在疫苗试验和阿尔兹海默病试验中,成功招募了15-21%的黑人、西语裔患者 [25][26][27] - 问:公司的三大服务中哪个最受客户欢迎 [30] 答:客户最初主要使用公司的患者招募服务,后逐步拓展到其他服务 [31][32] - 问:公司如何看待去中心化临床试验的发展 [34] 答:公司认为去中心化临床试验是将试验带到患者所在社区的趋势,这与公司的战略方向一致 [35][36] - 问:公司与制药公司的合作如何 [37][38] 答:公司与制药公司合作,利用社区药店为他们的试验招募患者,特别是少数群体患者 - 问:公司未来5-10年在临床试验领域的发展前景如何 [46][47] 答:公司认为药师和药店在未来临床试验中将扮演重要角色,公司将利用自身优势支持临床试验的去中心化发展

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/walgreens-boots-alliance-inc-loss-submission-form/?id=101231&from=3 ...